Anavex Life Sciences Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 10, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Market Cap	314	771	482	538	804	1,363
Market Cap Growth	-66.50%	60.15%	-10.40%	-33.17%	-40.97%	382.72%
Enterprise Value	186.27	668.77	349.45	386.51	655.21	1,211
Last Close Price	3.39	8.90	5.68	6.55	10.32	17.95
Forward PE	-	10.73	-	-	-	-
PB Ratio	2.54	8.13	4.00	3.79	5.65	9.04
P/TBV Ratio	2.45	8.00	3.94	3.68	5.57	8.31
Net Debt / Equity Ratio	-1.05	-1.08	-1.10	-1.06	-1.05	-1.01
Net Debt / EBITDA Ratio	3.30	2.00	2.50	2.71	2.93	3.62
Net Debt / FCF Ratio	-	2.63	4.29	5.44	6.15	5.01
Quick Ratio	18.18	11.56	8.80	12.27	14.92	14.93
Current Ratio	18.24	11.60	8.86	12.32	14.95	14.97
Return on Equity (ROE)	-8.87%	-43.11%	-32.81%	-33.41%	-32.47%	-42.28%
Return on Assets (ROA)	-29.57%	-42.95%	-36.47%	-36.32%	-32.44%	-42.82%
Return on Capital Employed (ROCE)	-31.06%	-47.79%	-40.35%	-39.22%	-34.77%	-47.18%
Buyback Yield / Dilution	-4.05%	-2.18%	-4.61%	-3.74%	-10.18%	-19.95%
Total Shareholder Return	-4.05%	-2.18%	-4.61%	-3.74%	-10.18%	-19.95%

SEC Filings: 10-K · 10-Q